Themis Medicare Ltd

Themis Medicare Ltd is currently rated 'Hold' by MarketsMOJO, with this rating last updated on 30 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's present position as of 03 August 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 1.86%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse to gauge future price direction.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading its MarketsMOJO grade from Sell to Hold as of 30 June 2026. This change reflects improving price action and technical indicators, suggesting a cautiously optimistic outlook amid mixed market returns and sector dynamics.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in daily price, the stock’s technical indicators present a complex picture, with some metrics signalling strength while others suggest caution. This article analyses the recent technical parameter changes, placing them in the context of broader market trends and the company’s performance relative to the Sensex.

Themis Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 23 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite a recent dip in daily price, the stock’s technical indicators, including MACD and moving averages, suggest improving momentum that could influence investor sentiment amid mixed return performance against the Sensex benchmark.

Themis Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Themis Medicare Ltd has exhibited a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early July 2026. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators present a complex picture, with some signals pointing to strength while others suggest caution. This article analyses the latest price action, momentum oscillators, and moving averages to provide a comprehensive view of the stock’s near-term outlook within the Pharmaceuticals & Biotechnology sector.

Themis Medicare Ltd has witnessed a notable shift in its technical momentum, upgrading from mildly bullish to bullish as of late June 2026. Despite a recent day decline of 3.94%, the pharmaceutical and biotechnology company’s technical indicators reveal a complex but improving picture, with key metrics such as MACD and moving averages signalling positive momentum. This article analyses the evolving technical landscape of Themis Medicare, contextualising its price action against broader market trends and providing insights for investors navigating this micro-cap stock.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the stock’s technical parameters reveal a cautiously optimistic outlook, prompting a reassessment of its market stance from Sell to Hold as of 30 June 2026.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading its overall trend from mildly bullish to bullish. Despite a slight dip in the daily price, key technical indicators such as MACD, moving averages, and KST signal an improving outlook, while some oscillators like RSI present cautionary notes. This nuanced technical landscape offers investors a balanced perspective on the stock’s near-term potential and risks.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 30 June 2026. This revision reflects a nuanced improvement across technical indicators and recent financial performance, despite persistent challenges in debt servicing and long-term profitability. The company’s Mojo Score now stands at 53.0, signalling a cautious but more optimistic stance among analysts.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum from mildly bearish to mildly bullish. Despite a recent day decline of 2.63%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, suggesting cautious optimism for investors analysing price momentum and trend dynamics.

The 50-day moving average for Themis Medicare Ltd has crossed above the 200-day moving average, creating a golden cross on 30 Jun 2026. However, this technical milestone coincided with a 2.63% decline in the stock price on the same day, while monthly momentum indicators remain bearish. The signal’s reliability is therefore clouded by conflicting data across multiple timeframes.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock exhibits a complex interplay of bullish and bearish signals across key technical indicators, reflecting a nuanced market sentiment as it trades near ₹112.25.

Themis Medicare Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a 2.99% gain on 24 Jun 2026, the stock remains graded as a Sell with a Mojo Score of 43.0, underscoring cautious investor sentiment amid mixed market signals.

Themis Medicare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.